Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT06037252
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Detailed Description
The study will include a screening period of up to 5 weeks. The primary endpoint will be at Week 44 with a tirzepatide extension until week 80. A safety follow up will be performed approximately 4 weeks after end of treatment.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Baseline in Body Weight
TimeFrame:
Baseline (Week 0), Week 44
Description:
Trial Information
NCT ID
NCT06037252
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025